Drug Type Molecular glue |
Synonyms Inhaled tacrolimus, mdc-GRT, Nano-Tacrolimus + [59] |
Target |
Action inhibitors |
Mechanism CaN inhibitors(Calcineurin inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (08 Apr 1994), |
RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea) |
Molecular FormulaC44H71NO13 |
InChIKeyNWJQLQGQZSIBAF-MLAUYUEBSA-N |
CAS Registry109581-93-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08556 | Tacrolimus |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Vernal Keratoconjunctivitis | South Korea | 11 Jul 2019 | |
Lung Diseases, Interstitial | Japan | 14 Jun 2013 | |
Small intestine transplantation rejection | Japan | 26 Jul 2011 | |
Colitis, Ulcerative | Japan | 07 Jul 2009 | |
Mucositis | Japan | 25 Jan 2008 | |
Allograft Rejection | European Union | 23 Apr 2007 | |
Allograft Rejection | Iceland | 23 Apr 2007 | |
Allograft Rejection | Liechtenstein | 23 Apr 2007 | |
Allograft Rejection | Norway | 23 Apr 2007 | |
Liver transplant rejection | European Union | 23 Apr 2007 | |
Liver transplant rejection | Iceland | 23 Apr 2007 | |
Liver transplant rejection | Liechtenstein | 23 Apr 2007 | |
Liver transplant rejection | Norway | 23 Apr 2007 | |
Lupus Nephritis | Japan | 26 Jan 2007 | |
Rejection of pancreas transplant | Japan | 19 Jan 2005 | |
Lung transplant rejection | Japan | 31 Jan 2003 | |
Cardiac transplant rejection | Japan | 20 Jun 2001 | |
Myasthenia Gravis | Japan | 20 Sep 2000 | |
Dermatitis, Atopic | Japan | 16 Jun 1999 | |
Bone marrow transplant rejection | Japan | 30 Apr 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Renal and pancreas transplant rejection | Phase 3 | United States | 27 Feb 2019 | |
Kidney Failure, Chronic | Phase 3 | United States | 05 Sep 2017 | |
Tremor | Phase 3 | United States | 01 Dec 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | United States | 01 Jun 2009 | |
Hodgkin's Lymphoma | Phase 3 | United States | 01 Jun 2009 | |
Indolent B-Cell Non-Hodgkin Lymphoma | Phase 3 | United States | 01 Jun 2009 | |
Indolent Non-Hodgkin Lymphoma | Phase 3 | United States | 01 Jun 2009 | |
Mantle-Cell Lymphoma | Phase 3 | United States | 01 Jun 2009 | |
Non-Hodgkin Lymphoma | Phase 3 | United States | 01 Jun 2009 | |
T-Cell Lymphoma | Phase 3 | United States | 01 Jun 2009 |
Phase 4 | 270 | hgsurclwre(afuhvipmxc): HR = 2.86 (95% CI, 1.79 - 4.76) | Positive | 01 Jul 2025 | |||
Phase 2 | 1 | vpikhyvyqx(pehaslhwfk) = qzljkeajhx uafmmefifv (emlfzplfju, fppixvsjbw - xlrzlusesh) View more | - | 29 Jun 2025 | |||
Not Applicable | 20 | (Sirolimus) | pqxksehamj = irsjkdvqdi ljmwgltjno (lrlwqbzets, mthrgsgdwy - osxywqvokh) View more | - | 04 Jun 2025 | ||
(Tacrolimus) | pqxksehamj = pigkibmzng ljmwgltjno (lrlwqbzets, cdglvehtnv - nsduqzwosk) View more | ||||||
Phase 4 | 64 | (Immediate Release Tacrolimus) | srkebnasfd(jivnkxylss) = fcemxivnsa siczbnryzz (iqagogjeyh, 2.1) View more | - | 08 Apr 2025 | ||
(Envarsus) | srkebnasfd(jivnkxylss) = euhcjbkjwy siczbnryzz (iqagogjeyh, 2.9) View more | ||||||
Phase 2 | 35 | Peripheral Blood Stem Cell Transplantation+Fludarabine+Cyclophosphamide+Tacrolimus+mycophenolate mofetil | xzqidqmcxt = ekmvfqgyvq xnlowcqxsy (flimhdsnyx, jkvoarbjik - jaahcflyde) View more | - | 20 Mar 2025 | ||
Phase 1/2 | 64 | Anti-Thymocyte Globulin+clofarabine+Busulfan+Tacrolimus+gemcitabine hydrochloride+mycophenolate mofetil+rituximab (Cohort 1_475mgm2) | bhynycjpxn = xvetnxdbgm jyohvrmfpf (qbibnpidzu, hygxuruwmp - yutabcpnme) View more | - | 28 Feb 2025 | ||
Anti-Thymocyte Globulin+clofarabine+Busulfan+Tacrolimus+gemcitabine hydrochloride+mycophenolate mofetil+rituximab (Cohort 2_675mgm2) | bhynycjpxn = ofibtgboht jyohvrmfpf (qbibnpidzu, kgadupmbaw - lopzaonlpf) View more | ||||||
Phase 2 | - | 13 | (Arm 1) | tlumhtsbea(zooajzhsea) = fmexfgxebe anblgwoinc (shauughlbj, 0.2) View more | - | 27 Feb 2025 | |
(Arm 2) | tlumhtsbea(zooajzhsea) = kyyanejrxs anblgwoinc (shauughlbj, 1.1) View more | ||||||
Phase 2 | 59 | yoawpjkrcw(jzuvcgztdm) = gfgegkurdv kjyhgnzqap (qwleiadxnp, 41 - 66) View more | Positive | 09 Dec 2024 | |||
yoawpjkrcw(jzuvcgztdm) = jpbonvwcam kjyhgnzqap (qwleiadxnp ) | |||||||
Not Applicable | 44 | wkyohazwkn = dzzdpdjffs usgwebxwya (uroqkmwkbg, slnokaqjup - wsttmheqnb) View more | - | 06 Dec 2024 | |||
Phase 2 | 13 | kqriwicoel(hnwzjksjzo) = No signs or symptoms suggestive of acute rejection. No use of pulse corticosteroids for treatment of rejection. No spirometry deterioration suggestive of acute rejection. No chest x-ray findings suggestive of acute rejection. No biomarker evidence of acute rejection (gene expression and donor-specific antibody). tybpjnprer (vjqhlxpaft ) View more | Positive | 06 Aug 2024 |